| Indicators | Browse All

Evaxion A/S (EVAX)

Healthcare | Biotechnology | Horsholm, Denmark | NasdaqCM
3.02 USD -0.15 (-4.732%) ⇩ (July 13, 2026, 4 p.m. EDT)

Short-term:★☆☆☆☆Long-term:⯪☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | July 11, 2026, 4:22 a.m. EDT

The immediate outlook is severely clouded by a relentless multi-year price collapse, with the stock down nearly 99% over the last four years and posting negative returns for every single year in that span. While recent headlines highlight promising Phase 2 data for a cancer vaccine, the market has already priced in a catastrophic failure of the business model, evidenced by the stock trading at a forward P/E of 79 despite reporting losses and negative operating margins. The balance sheet shows significant distress with negative returns on equity and assets, and the lack of any analyst recommendations suggests deep skepticism about the path to profitability. With no dividend history to speak of and a technical structure that remains well below its moving averages, there is no safe entry point for a short-term trade, and the fundamental deterioration makes a long-term hold highly speculative at best.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
MSTL ✓0.132505
AutoETS0.137157
AutoARIMA0.137159
AutoTheta0.209449

Forecast horizon: 45 days | Selected: MSTL

Forecast Reliability
Score 33%
H-stat 31.46
Ljung-Box p 0.000
Jarque-Bera p 0.257
Excess Kurtosis -1.02
Attribute Value
Sector Healthcare
Revenue per Share 1.059
Market Cap 25,187,450
Forward P/E 75.50
Beta 0.26
Profit Margins -129.60%
Previous Name Evaxion Biotech A/S
Website https://evaxion.ai

Info Dump

Attribute Value
52 Week Change 0.18726587
Address1 Dr. Neergaards Vej
Address2 5th Floor
All Time High 1,252.0
All Time Low 1.2
Ask 3.9
Ask Size 2
Average Daily Volume10 Day 21,310
Average Daily Volume3 Month 30,265
Average Volume 30,265
Average Volume10Days 21,310
Beta 0.263
Bid 2.31
Bid Size 2
Book Value 1.584
City Horsholm
Compensation As Of Epoch Date 1,767,139,200
Country Denmark
Crypto Tradeable 0
Currency USD
Current Price 3.02
Custom Price Alert Confidence HIGH
Date Short Interest 1,782,777,600
Day High 3.22
Day Low 3.02
Earnings Call Timestamp End 1,748,349,000
Earnings Call Timestamp Start 1,748,349,000
Earnings Timestamp End 1,755,520,200
Earnings Timestamp Start 1,755,001,800
Ebitda -8,824,500
Ebitda Margins -1.17222
Enterprise To Ebitda -0.765
Enterprise To Revenue 0.896
Enterprise Value 6,747,449
Eps Current Year -0.04
Eps Forward 0.04
Eps Trailing Twelve Months -0.96
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 3.7613
Fifty Day Average Change -0.7413001
Fifty Day Average Change Percent -0.19708614
Fifty Two Week Change Percent 18.726587
Fifty Two Week High 12.15
Fifty Two Week High Change -9.129999
Fifty Two Week High Change Percent -0.7514403
Fifty Two Week Low 2.45
Fifty Two Week Low Change 0.56999993
Fifty Two Week Low Change Percent 0.23265304
Fifty Two Week Range 2.45 - 12.15
Financial Currency USD
First Trade Date Milliseconds 1,612,535,400,000
Float Shares 5,679,353
Forward Eps 0.04
Forward P E 75.5
Full Exchange Name NasdaqCM
Full Time Employees 46
Gmt Off Set Milliseconds -14,400,000
Gross Margins 1.0
Gross Profits 7,528,000
Has Pre Post Market Data 1
Held Percent Insiders 0.17469
Held Percent Institutions 0.09401
Implied Shares Outstanding 8,340,215
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ipo Expected Date 2,021-02-05
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,736,812,800
Last Split Factor 1:5
Long Business Summary Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Long Name Evaxion A/S
Market us_market
Market Cap 25,187,450
Market State PRE
Max Age 86,400
Message Board Id finmb_319014926
Most Recent Quarter 1,774,915,200
Name Change Date 2,026-07-13
Net Income To Common -9,756,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 26,438,481
Number Of Analyst Opinions 4
Open 3.22
Operating Margins -1.22011
Payout Ratio 0.0
Phone 45 53 53 18 50
Prev Name Evaxion Biotech A/S
Previous Close 3.17
Price Eps Current Year -75.5
Price Hint 4
Price To Book 1.9065657
Price To Sales Trailing12 Months 3.3458354
Profit Margins -1.29596
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.15
Regular Market Change Percent -4.73186
Regular Market Day High 3.22
Regular Market Day Low 3.02
Regular Market Day Range 3.02 - 3.22
Regular Market Open 3.22
Regular Market Previous Close 3.17
Regular Market Price 3.02
Regular Market Time 1,783,972,800
Regular Market Volume 14,523
Return On Assets -0.23488002
Return On Equity -0.82931
Revenue Per Share 1.059
Sand P52 Week Change 0.20847368
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 8,340,215
Shares Percent Shares Out 0.0034999999
Shares Short 29,391
Shares Short Previous Month Date 1,780,012,800
Shares Short Prior Month 24,851
Short Name Evaxion A/S
Short Percent Of Float 0.0043
Short Ratio 0.94
Source Interval 15
Symbol EVAX
Target High Price 16.0
Target Low Price 9.0
Target Mean Price 11.25
Target Median Price 10.0
Total Cash 18,440,000
Total Cash Per Share 2.211
Total Debt 0
Total Revenue 7,528,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -0.96
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 4.486375
Two Hundred Day Average Change -1.4663749
Two Hundred Day Average Change Percent -0.3268507
Type Disp Equity
Volume 14,523
Website https://evaxion.ai
Zip 2,970